country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-164702

Copy Link Print Information

BL-B01D1

(Synonyms: Izalontamab Brengitecan)

Customer Review

Based on 1 Customer Validation

BL-B01D1 (Izalontamab Brengitecan) is a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, formed by conjugating the EGFR/HER3 bispecific antibody Izalontamab (HY-P99676) to a novel TOP-I inhibitor payload Deruxtecan 2-hydroxypropanamide (HY-153891) via a cleavable linker (Mc-Gly-Gly-Phe-Gly). BL-B01D1 binds to EGFR and HER3 on the surface of tumor cells, mediates endocytosis and releases the payload, inhibits topoisomerase I, blocks DNA replication and RNA synthesis, and disrupts DNA structure. BL-B01D1 induces cell cycle S-phase arrest, apoptosis, antibody-dependent cell-mediated cytotoxicity, and tumor cell death. BL-B01D1 can be used for cancer research.

For research use only. We do not sell to patients.

Purity: 99.65%
Molecular Weight:205830.00

Storage:

-80°C, protect from light

BL-B01D1 Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biological Activity
- Description
- IC₅₀ & Target
- In Vivo
- Clinical Trial
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]^[3]^[4]^[5]

Topoisomerase I

EGFR

HER3

All EGFR Isoforms :

All Topoisomerase Isoforms :

In Vivo

BL-B01D1 (Izalontamab Brengitecan) exhibits superior in vivo antitumor activity compared to single-target EGFR or HER3 antibody-drug conjugates in cancer-patient-derived tumor xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

Appearance Liquid
Molecular Weight 205830.00
Color Colorless to light yellow
SMILES

[BL-B01D1]
Synonyms

Izalontamab Brengitecan
Shipping

Shipping with dry ice.
Storage

-80°C, protect from light

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wan W, et al. Abstract 2642: BL‑B01D1, a novel EGFR×HER3‑targeting ADC, demonstrates robust anti‑tumor efficacy in preclinical evaluation. Cancer Research. 2023 Apr 4;83(7_Supplement):2642.

[2]. Liu C, et al. A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2025 Oct;31(10):3485-3491.

[3]. Ma Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024 Jul;25(7):901-911. [Content Brief]

[4]. Bian X, et al. Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025 Nov 10;43(32):3505-3515.

[5]. Zhang L, et al. BL‑B01D1, a first‑in‑class EGFR×HER3 bispecific antibody‑drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first‑in‑human phase 1 study. Journal of Clinical Oncology. 2023 Jun;41(16_suppl):3001.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vivo
- Clinical Trial
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

BL-B01D1

Becotatug vedotin

Izalontamab

Patritumab deruxtecan

Datopotamab deruxtecan (solution)

Amivantamab

Telisotuzumab Adizutecan

Ifinatamab deruxtecan

Trastuzumab deruxtecan

Cetuximab

Deruxtecan

Deruxtecan 2-hydroxypropanamide

Enfortumab vedotin-ejfv

All EGFR Isoforms

All Topoisomerase Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Bioz

BL-B01D1

Becotatug vedotin

Izalontamab

Patritumab deruxtecan

Datopotamab deruxtecan (solution)

Amivantamab

Telisotuzumab Adizutecan

Ifinatamab deruxtecan

Trastuzumab deruxtecan

Cetuximab

Deruxtecan

Deruxtecan 2-hydroxypropanamide

Enfortumab vedotin-ejfv

All EGFR Isoforms

All Topoisomerase Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

BL-B01D1 Related Classifications

HY-164702 Related Classifications

Bioz